Erasca, Inc. (ERAS): Free Cash Flow
-$95.58M
Year ended 2025-12-31
-$98.08M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$95.58M | n/m | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | -$109.48M | n/m | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | -$102.99M | n/m | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | -$117.81M | n/m | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | -$90.81M | n/m | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | -$33.63M | n/a | 2022-03-24, From 2020-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Erasca, Inc. (ERAS) | 2025-12-31 | -$95.58M | n/m |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $127.01M | +22.8% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | -$139.93M | n/m |
| Harrow, Inc. (HROW) | 2025-12-31 | $42.98M | n/m |
| Nkarta, Inc. (NKTX) | 2025-12-31 | -$89.91M | n/m |
| MBX Biosciences, Inc. (MBX) | 2025-12-31 | -$81.88M | n/m |
| Oric Pharmaceuticals, Inc. (ORIC) | 2025-12-31 | -$111.68M | n/m |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | -$172.35M | n/m |
| Alumis Inc. (ALMS) | 2025-12-31 | -$370.18M | n/m |
Compare ERAS, IRWD, TNGX, HROW side by side · Screen every company in Pharmaceutical Preparations ↗